A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/165 (2006.01) A61K 31/196 (2006.01) A61K 31/4525 (2006.01) A61K 31/551 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2736623
The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-ß-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.
La présente invention concerne dans un premier temps un produit contenant au moins un agent bloquant les connexines et une drogue psychotrope, comme produits de combinaison pour une utilisation simultanée, séparée ou étalée dans le temps, chez des patients souffrant de troubles psychiatriques et/ou neurodégénératifs. Avantageusement, l'agent bloquant les connexines est choisi dans le groupe comprenant l'acide méclofénamique, l'acide 18-.beta.-glycyrrhétinique, le carbenoxolone, la méfloquine et le 2-APB, et est préférentiellement l'acide méclofénamique.
Charveriat Mathieu
Deslys Jean-Philippe
Iris Francois
Mouthon Franck
Bio Modeling Systems Ou Bmsystems
Commissariat A. L'energie Atomique Et Aux Energies Alternatives
Fasken Martineau Dumoulin Llp
LandOfFree
Use of anti-connexin agents for modulating the therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-connexin agents for modulating the therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-connexin agents for modulating the therapeutic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1525030